Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.52 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999197 | 0.78 | DPP4 (0.51) | DPP4DPP8MAPTKMT2AATM | |
| SCHEMBL14369438 | 0.73 | DPP4 (0.47) | DPP4DPP8MAPTKMT2A | |
| SCHEMBL3149113 | 0.68 | DPP4 (1.00) | DPP4DPP8 | |
| SCHEMBL27925971 | 0.63 | KEAP1 (0.59) | DPP4DPP8IKBKBPARP1PDK2 | |
| SCHEMBL27722279 | 0.63 | LMNA (0.51) | DPP4DPP8ADRA1DMAPTKMT2A | |
| SCHEMBL2001399 | 0.63 | DPP4 (0.42) | DPP4MAPT | |
| SCHEMBL1203519 | 0.62 | BCAT2 (0.59) | IKBKBPARP1MAPTKMT2AATM | |
| SCHEMBL29940950 | 0.62 | BCAT2 (0.59) | IKBKBPARP1MAPTKMT2AATM | |
| SCHEMBL1992724 | 0.62 | DPP4 (0.46) | DPP4PARP1 | |
| SCHEMBL8903347 | 0.62 | PARP1 (0.35) | PARP1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | claimed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | claimed |
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007112347-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP3, DPP4, DPP7 | DPP4 2/4885DPP8 5/4885IKBKB 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.